ArticleBMC oral health2026
Material-dependent effects of injectable platelet rich-fibrin on growth factor release, inflammation, and osteoclast activity: an in vitro study.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundInjectable platelet-rich fibrin (i-PRF) is often used in maxillofacial surgery in combination with commercially available materials, but until now no study has compared biological and mechanical interactions between i-PRF and different composition biomaterial scaffolds. This study investigated how biomaterials - Collacone® (Biotiss), Bio-Oss® Collagen (90% Geistlich Bio-Oss®/10% porcine collagen, Geistlich), and CeraForm® (65% hydroxyapatite/35% β-tricalcium phosphate, Teknimed) - interact with i-PRF and influence material degradation, growth factor release, osteoblastogenesis, and osteoclastogenesis.
methodsBlood from three healthy donors was centrifuged at 700 rpm for 5 min to prepare i-PRF. Materials were impregnated with i-PRF and allowed to coagulate for 30 min. Surface properties were examined by scanning electron microscopy, and material degradation was monitored for 50 days. Growth factor release (IL-6, IL-8, EGF, PDGF, TGF-β1) was quantified by ELISA over 14 days. Osteoblastogenesis was evaluated using CellTiter-Blue®, and osteoclastogenesis was assessed through resorption assays on simulated body fluid/collagen type I-coated plates via image analysis and qPCR for differentiation markers. Data was analysed using ANOVA.
resultsi-PRF delays the degradation of collagen-containing biomaterials. Impregnation of studied biomaterials with i-PRF only reduced growth factor release during the first 6 h. TGF-β1 release increased significantly after platelet activation by foreign surfaces, while collagen-based biomaterials triggered rapid IL-6 and IL-8 release. Composites with i-PRF promoted earlier activation of both osteoclasts and osteoblasts.
conclusioni-PRF showed different synergetic responses based on collagen and calcium phosphate composition in materials it was combined with. Meaning that these findings provide guidance for optimizing biomaterial and i-PRF combinations in surgical applications and inform the design of next-generation PRF-material composites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.